Pharmaceuticals

24 pages, 4325 KiB

Open AccessArticle

Developing a Chromatographic Method for Quantifying Latanoprost and Related Substances in Glaucoma Treatments

by Katarzyna Asendrych-Wicik, Katarzyna Malik and Magdalena Markowicz-Piasecka

Pharmaceuticals 2025, 18(5), 619; https://doi.org/10.3390/ph18050619 - 24 Apr 2025

Background/Objectives: Latanoprost is a leading active pharmaceutical ingredient belonging to the synthetic prostaglandin F2α analogs, widely used as a first-line treatment for open-angle glaucoma and increased intraocular pressure. This study addresses the critical need for an accurate and precise chromatographic method that [...] Read more.

Background/Objectives: Latanoprost is a leading active pharmaceutical ingredient belonging to the synthetic prostaglandin F2α analogs, widely used as a first-line treatment for open-angle glaucoma and increased intraocular pressure. This study addresses the critical need for an accurate and precise chromatographic method that is capable of simultaneously quantifying latanoprost and six latanoprost-related substances in antiglaucoma eye drops. This will be crucial for patient safety and treatment efficacy. This method enables the separation of latanoprost isomers, (15S)-latanoprost, latanoprost enantiomer, and 5,6-trans latanoprost from latanoprost signal. Furthermore, it is specific for the well-known latanoprost degradants—the major latanoprost acid and the minor 15-ketolatanoprost—as well as synthetic derivatives, such as triphenylphosphine oxide (TPPO) and propan-2-yl 5-(diphenylphosphoryl)pentanoate (IDPP). Using forced degradation studies using high temperatures, UV light, alkalis, acids, and oxidizing agents, the degradation profiles of the drugs were characterized and the method’s stability-indicating power was confirmed. Methods: Separation was achieved on a stationary combined system comprising chiral and cyano columns. Reverse-phase gradient elution and UV 210 nm detection were employed. The novel method was validated according to the European Medicines Agency International Council for Harmonisation Q2 Validation of analytical procedures—Scientific guideline. Results: The method was shown to be linear in the range of 40–60 µg/mL for latanoprost and 0.05–2.77 µg/mL for related substances, confirmed by a correlation coefficient of r = 0.999. Recoveries for latanoprost were obtained within the range of 98.0–102.0% for assays and 90.0–110.0% for impurities. The detection and quantification limits for latanoprost were 0.025 µg/mL and 0.35 µg/mL, respectively. Conclusions: The analytical procedure developed is adequately sensitive, precise, and accurate compared to existing methods. The method can be reliably used to control the critical quality attributes of low-dose latanoprost products, ensuring their required high pharmaceutical quality, which translates into improvements in patient care. This advancement holds significant implications for enhancing the therapeutic management of glaucoma, ensuring drug safety and efficacy. Full article

(This article belongs to the Special Issue Advances in Drug Analysis and Drug Development)

► Show Figures

Graphical abstract

22 pages, 19376 KiB

Open AccessArticle

Exploring Therapeutic Potential of Bi-Qi Capsules in Treatment of Gout by Discovering Crucial Drug Targets

by Jing Xie, Yu Zhang, Rong Ren, Ruizhen Bu, Liying Chen, Juezhuo Hou, Dandan Shang, Yadong Liu, Dan Wang, Tao Wang and Hong Zhou

Pharmaceuticals 2025, 18(5), 618; https://doi.org/10.3390/ph18050618 - 24 Apr 2025

Abstract

Objectives: This research aims to explore the therapeutic potential of Bi-Qi capsules in the treatment of gout by identifying crucial drug targets through a multidimensional data analysis strategy. Methods: Bi-Qi capsule drug targets and differentially expressed genes (DEGs) of gout were [...] Read more.

Objectives: This research aims to explore the therapeutic potential of Bi-Qi capsules in the treatment of gout by identifying crucial drug targets through a multidimensional data analysis strategy. Methods: Bi-Qi capsule drug targets and differentially expressed genes (DEGs) of gout were derived from public databases, such as Swiss Target Prediction, STITCH, and the GEO database. Subsequently, the overlapped targets were analyzed to elucidate the potential therapeutic mechanism and to identify candidate targets of Bi-Qi capsules against gout. Next, Mendelian randomization (MR) analysis was employed to screen and explore the causal relationship between candidate targets and gout. Finally, single-cell RNA sequencing (scRNA-seq), gene set enrichment analysis (GSEA), transcription factor and ceRNA regulatory networks, and molecular docking were performed to validate the role of the crucial targets of Bi-Qi capsules in the treatment of gout. Results: A total of 46 candidate targets were identified, in which KCNA5, PTGS2, and TNF exhibited significant causal relationships with gout (p < 0.05) and were regarded as the crucial targets. Through scRNA-seq and gene labeling, crucial targets were found to be expressed in eighteen cell clusters and eight cell types, which are closely associated with carbohydrate metabolism, nerve conduction, and the innate immunity process. Bi-Qi capsule active compounds such as tanshinone IIA, strychnine, tanshinaldehyde, cryptotanshinone, tumulosic acid, and glycyrrhetic acid exhibit a better binding ability to crucial targets. Conclusions: The results not only elucidate the anti-gout mechanism of Bi-Qi capsules but also provide an insight into multi-target natural medication for metabolic disease treatment, which contributes to guiding the clinical application of Bi-Qi capsules in the future. Full article

(This article belongs to the Section Pharmacology)

► Show Figures

Figure 1

23 pages, 8189 KiB

Open AccessReview

Exploring Macrocyclic Chemical Space: Strategies and Technologies for Drug Discovery

by Taegwan Kim, Eunbee Baek and Jonghoon Kim

Pharmaceuticals 2025, 18(5), 617; https://doi.org/10.3390/ph18050617 - 24 Apr 2025

Abstract

Macrocycles have emerged as significant therapeutic candidates in drug discovery due to their unique capacity to target complex and traditionally inaccessible biological interfaces. Their structurally constrained three-dimensional configurations facilitate high-affinity interactions with challenging targets, notably protein–protein interfaces. However, despite their potential, the synthesis [...] Read more.

Macrocycles have emerged as significant therapeutic candidates in drug discovery due to their unique capacity to target complex and traditionally inaccessible biological interfaces. Their structurally constrained three-dimensional configurations facilitate high-affinity interactions with challenging targets, notably protein–protein interfaces. However, despite their potential, the synthesis and optimization of macrocyclic compounds present considerable challenges related to structural complexity, synthetic accessibility, and the attainment of favorable drug-like properties, particularly cell permeability and oral bioavailability. Recent advancements in synthetic methodologies have expanded the chemical space accessible to macrocycles, enabling the creation of structurally diverse and pharmacologically active compounds. Concurrent developments in computational strategies have further enhanced macrocycle design, providing valuable insights into structural optimization and predicting molecular properties essential for therapeutic efficacy. Additionally, a deeper understanding of macrocycles’ conformational adaptability, especially their ability to internally shield polar functionalities to improve membrane permeability, has significantly informed their rational design. This review discusses recent innovations in synthetic and computational methodologies that have advanced macrocycle drug discovery over the past five years. It emphasizes the importance of integrating these strategies to overcome existing challenges, illustrating how their synergy expands the therapeutic potential and chemical diversity of macrocycles. Selected case studies underscore the practical impact of these integrated approaches, highlighting promising therapeutic applications across diverse biomedical targets. Full article

(This article belongs to the Special Issue Advances in the Synthesis and Application of Heterocyclic Compounds)

► Show Figures

Graphical abstract

25 pages, 6242 KiB

Open AccessArticle

Development and Characterization of an Injectable Alginate/Chitosan Composite Hydrogel Reinforced with Cyclic-RGD Functionalized Graphene Oxide for Potential Tissue Regeneration Applications

by Mildred A. Sauce-Guevara, Sergio D. García-Schejtman, Emilio I. Alarcon, Sergio A. Bernal-Chavez and Miguel A. Mendez-Rojas

Pharmaceuticals 2025, 18(5), 616; https://doi.org/10.3390/ph18050616 - 23 Apr 2025

Abstract

Background: In tissue engineering, developing injectable hydrogels with tailored mechanical and bioactive properties remains a challenge. This study introduces an injectable hydrogel composite for soft tissue regeneration, composed of oxidized alginate (OA) and N-succinyl chitosan (NSC) cross-linked via Schiff base reaction, reinforced with [...] Read more.

Background: In tissue engineering, developing injectable hydrogels with tailored mechanical and bioactive properties remains a challenge. This study introduces an injectable hydrogel composite for soft tissue regeneration, composed of oxidized alginate (OA) and N-succinyl chitosan (NSC) cross-linked via Schiff base reaction, reinforced with graphene oxide (GOx) and cyclic arginylglycylaspartic acid (c-RGD). The objective was to create a multifunctional platform combining injectability, bioactivity, and structural stability. Methods: The OA/NSC/GOx-cRGD hydrogel was synthesized through Schiff base cross-linking (aldehyde-amine reaction). Characterization included FTIR (C=N bond at 1650 cm⁻¹), Raman spectroscopy (D/G bands at 1338/1567 cm⁻¹), SEM (porous microstructure), and rheological analysis (shear-thinning behavior). In vitro assays assessed fibroblast viability (MTT) and macrophage TNF-α secretion (ELISA), while ex-vivo injectability and retention were evaluated using chicken cardiac tissue. Results: The hydrogel exhibited shear-thinning behavior (viscosity: 10 to <1 Pa·s) and elastic-dominated mechanics (G′ > G″), ensuring injectability. SEM revealed an interconnected porous structure mimicking native extracellular matrix. Fibroblast viability remained ≥95%, and TNF-α secretion in macrophages decreased by 80% (30 vs. 150 pg/μL in controls), demonstrating biocompatibility and anti-inflammatory effects. The hydrogel adhered stably to cardiac tissue without leakage. Conclusions: The OA/NSC/GOx-cRGD composite integrates injectability, bioactivity, and structural stability, offering a promising scaffold for tissue regeneration. Its modular design allows further functionalization with peptides or growth factors. Future work will focus on translational applications, including scalability and optimization for dynamic biological environments. Full article

(This article belongs to the Section Biopharmaceuticals)

► Show Figures

Graphical abstract

29 pages, 700 KiB

Open AccessReview

Advancements in Nanocarrier Systems for Nose-to-Brain Drug Delivery

by Thi-Thao-Linh Nguyen and Van-An Duong

Pharmaceuticals 2025, 18(5), 615; https://doi.org/10.3390/ph18050615 - 23 Apr 2025

Abstract

In recent decades, nose-to-brain drug delivery has shown effectiveness in treating many central nervous system diseases. Intranasally administered drugs can be delivered to the brain through the olfactory and trigeminal pathways that bypass the blood–brain barrier. However, nose-to-brain drug delivery is challenging due [...] Read more.

In recent decades, nose-to-brain drug delivery has shown effectiveness in treating many central nervous system diseases. Intranasally administered drugs can be delivered to the brain through the olfactory and trigeminal pathways that bypass the blood–brain barrier. However, nose-to-brain drug delivery is challenging due to the inadequate nasal mucosa absorption of drugs and the short retention time of the intranasal formulations. These problems can be minimized through the use of nano-drug delivery systems, such as micelles, polymeric nanoparticles, nanoemulsions, liposomes, solid lipid nanoparticles, and nanostructured lipid carriers. They can enhance the drug’s bioavailability in the brain via increases in drug solubility, permeation, and stability. Nose-to-brain nano-drug delivery systems have been evaluated in vivo by a number of research groups. This review aims to provide an overview of nose-to-brain delivery and recent advances in the development of nano-drug delivery systems for delivering drugs from the nose to the brain to improve the treatment of some central nervous system diseases. Full article

(This article belongs to the Special Issue Recent Advances in Nanocarriers for Drug Delivery)

40 pages, 1048 KiB

Open AccessReview

Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease

by Melinda Urkon, Elek Ferencz, József Attila Szász, Monica Iudita Maria Szabo, Károly Orbán-Kis, Szabolcs Szatmári and Előd Ernő Nagy

Pharmaceuticals 2025, 18(5), 614; https://doi.org/10.3390/ph18050614 - 23 Apr 2025

Abstract

In addition to the classically accepted pathophysiological features of Alzheimer’s disease (AD), increasing attention is paid to the role of the insulin-resistant state of the central nervous system. Glucagon-like peptide-1 receptor (GLP-1R) agonism demonstrated neuroprotective consequences by mitigating neuroinflammation and oxidative damage. The [...] Read more.

In addition to the classically accepted pathophysiological features of Alzheimer’s disease (AD), increasing attention is paid to the role of the insulin-resistant state of the central nervous system. Glucagon-like peptide-1 receptor (GLP-1R) agonism demonstrated neuroprotective consequences by mitigating neuroinflammation and oxidative damage. The present review aims to offer a comprehensive overview of the neuroprotective properties of GLP-1R agonists (GLP-1RAs), with a particular focus on experimental animal models of AD. Ameliorated amyloid-β plaque and neurofibrillary tangle formation and deposition following exenatide, liraglutide, and lixisenatide treatment was confirmed in several models. The GLP-1RAs studied alleviated central insulin resistance, as evidenced by the decreased serine phosphorylation of insulin receptor substrate 1 (IRS-1) and restored downstream phosphoinositide 3-kinase/RAC serine/threonine–protein kinase (PI3K/Akt) signaling. Furthermore, the GLP-1RAs influenced multiple mitogen-activated protein kinases (extracellular signal-regulated kinase: ERK; c-Jun N-terminal kinase: JNK, p38) positively and suppressed glycogen synthase kinase 3 (GSK-3β) hyperactivation. A lower proportion of reactive microglia and astrocytes was associated with better neuronal preservation following their administration. Finally, restoration of cognitive functions, particularly spatial memory, was also observed for semaglutide and dulaglutide. GLP-1RAs, therefore, hold promising disease-modifying potential in the management of AD. Full article

(This article belongs to the Special Issue Neurodegenerative Disorders: Computer – Aided Drug Design, Еxperimental Аpproaches and Mechanisms)

► Show Figures

Graphical abstract

28 pages, 16481 KiB

Open AccessArticle

Systems Biology-Driven Discovery of Host-Targeted Therapeutics for Oropouche Virus: Integrating Network Pharmacology, Molecular Docking, and Drug Repurposing

by Pranab Dev Sharma, Abdulrahman Mohammed Alhudhaibi, Abdullah Al Noman, Emad M. Abdallah, Tarek H. Taha and Himanshu Sharma

Pharmaceuticals 2025, 18(5), 613; https://doi.org/10.3390/ph18050613 - 23 Apr 2025

Abstract

Background: Oropouche virus (OROV), part of the Peribunyaviridae family, is an emerging pathogen causing Oropouche fever, a febrile illness endemic in South and Central America. Transmitted primarily through midge bites (Culicoides paraensis), OROV has no specific antiviral treatment or vaccine. This [...] Read more.

Background: Oropouche virus (OROV), part of the Peribunyaviridae family, is an emerging pathogen causing Oropouche fever, a febrile illness endemic in South and Central America. Transmitted primarily through midge bites (Culicoides paraensis), OROV has no specific antiviral treatment or vaccine. This study aims to identify host-targeted therapeutics against OROV using computational approaches, offering a potential strategy for sustainable antiviral drug discovery. Methods: Virus-associated host targets were identified using the OMIM and GeneCards databases. The Enrichr and DSigDB platforms were used for drug prediction, filtering compounds based on Lipinski’s rule for drug likeness. A protein–protein interaction (PPI) network analysis was conducted using the STRING database and Cytoscape 3.10.3 software. Four key host targets—IL10, FASLG, PTPRC, and FCGR3A—were prioritized based on their roles in immune modulation and OROV pathogenesis. Molecular docking simulations were performed using the PyRx software to evaluate the binding affinities of selected small-molecule inhibitors—Acetohexamide, Deptropine, Methotrexate, Retinoic Acid, and 3-Azido-3-deoxythymidine—against the identified targets. Results: The PPI network analysis highlighted immune-mediated pathways such as Fc-gamma receptor signaling, cytokine control, and T-cell receptor signaling as critical intervention points. Molecular docking revealed strong binding affinities between the selected compounds and the prioritized targets, suggesting their potential efficacy as host-targeting antiviral candidates. Acetohexamide and Deptropine showed strong binding to multiple targets, indicating broad-spectrum antiviral potential. Further in vitro and in vivo validations are needed to confirm these findings and translate them into clinically relevant treatments. Conclusions: This study highlights the potential of using computational approaches to identify host-targeted therapeutics for Oropouche virus (OROV). By targeting key host proteins involved in immune modulation—IL10, FASLG, PTPRC, and FCGR3A—the selected compounds, Acetohexamide and Deptropine, demonstrate strong binding affinities, suggesting their potential as broad-spectrum antiviral candidates. Further experimental validation is needed to confirm their efficacy and potential for clinical application, offering a promising strategy for sustainable antiviral drug discovery. Full article

(This article belongs to the Special Issue Computational Methods in Drug Development)

► Show Figures

Graphical abstract

26 pages, 4056 KiB

Open AccessArticle

Epigallocatechin Gallate in Camellia sinensis Ameliorates Skin Aging by Reducing Mitochondrial ROS Production

by Ji Ho Park, Eun Young Jeong, Ye Hyang Kim, So Yoon Cha, Ha Yeon Kim, Yeon Kyung Nam, Jin Seong Park, So Yeon Kim, Yoo Jin Lee, Jee Hee Yoon, Byeonghyeon So, Duyeol Kim, Minseon Kim, Youngjoo Byun, Yun Haeng Lee, Song Seok Shin and Joon Tae Park

Pharmaceuticals 2025, 18(5), 612; https://doi.org/10.3390/ph18050612 - 23 Apr 2025

Abstract

Background: Reactive oxygen species (ROS) generated by mitochondrial dysfunction damage cellular organelles and contribute to skin aging. Therefore, strategies to reduce mitochondrial ROS production are considered important for alleviating skin aging, but no effective methods have been identified. Methods: In this study, we [...] Read more.

Background: Reactive oxygen species (ROS) generated by mitochondrial dysfunction damage cellular organelles and contribute to skin aging. Therefore, strategies to reduce mitochondrial ROS production are considered important for alleviating skin aging, but no effective methods have been identified. Methods: In this study, we evaluated substances utilized as cosmetic ingredients and discovered Camellia sinensis (C. sinensis) as a substance that reduces mitochondrial ROS levels. Results: C. sinensis extracts were found to act as senolytics that selectively kill senescent fibroblasts containing dysfunctional mitochondria. In addition, C. sinensis extracts facilitated efficient electron transport in the mitochondrial electron transport chain (ETC) by increasing the efficiency of oxidative phosphorylation (OXPHOS), thereby reducing mitochondrial ROS production, a byproduct of the inefficient ETC. This novel mechanism of C. sinensis extracts led to the restoration of skin aging and the skin barrier. Furthermore, epigallocatechin gallate (EGCG) was identified as an active ingredient that plays a key role in C. sinensis extract-mediated skin aging recovery. Indeed, similar to C. sinensis extracts, EGCG reduced ROS and improved skin aging in an artificial skin model. Conclusions: Our data uncovered a novel mechanism by which C. sinensis extract reverses skin aging by reducing mitochondrial ROS production via selective senescent cell death/increased OXPHOS efficiency. Our results suggest that C. sinensis extract or EGCG may be used as a therapeutic agent to reverse skin aging in clinical and cosmetic applications. Full article

(This article belongs to the Special Issue Antioxidants in the Processes of Retarding Ageing)

► Show Figures

Figure 1

20 pages, 2428 KiB

Open AccessArticle

A Short-Chain Analogue of Seminolipid: Synthesis and Inhibitory Effect on Mouse Fertilization

by Seung Gee Lee, Leila Vahdati, Laura Morelli, Luigi Panza, Federica Compostella and Nongnuj Tanphaichitr

Pharmaceuticals 2025, 18(5), 611; https://doi.org/10.3390/ph18050611 - 23 Apr 2025

Abstract

Background/Objectives: Seminolipid (sulfogalactosylglycerolipid (SGG)) is abundantly present on the sperm surface and its roles in sperm–egg interaction are well-documented. SGG liposomes have direct affinity for the zona pellucida (ZP), the egg extracellular matrix. SGG is also integral to the formation of sperm lipid [...] Read more.

Background/Objectives: Seminolipid (sulfogalactosylglycerolipid (SGG)) is abundantly present on the sperm surface and its roles in sperm–egg interaction are well-documented. SGG liposomes have direct affinity for the zona pellucida (ZP), the egg extracellular matrix. SGG is also integral to the formation of sperm lipid rafts, which are platforms on the sperm surface for ZP binding. Our objective was to chemically synthesize a short-chain analog of SGG (SC-SGG with a C6 acyl chain instead of C16 in the natural lipid), which is solubilized in an aqueous environment, and to determine the inhibitory effects of SC-SGG in mouse sperm–egg interaction, and thus fertilization. Methods: SC-SGG was synthesized from a 3-O-galactopyranosyl-sn-glycerol intermediate protected on the sugar moiety through the acylation of glycerol with caproic acid, deprotection and regioselective 3-O-sulfation of the galactose residue. SC-SGG solubilized in a medium was used to treat sperm–egg co-incubates or to pretreat sperm or eggs before co-incubating sperm with eggs or vice versa. Sperm–ZP binding and fertilization (scoring eggs with two pronuclei) were microscopically assessed. Results: SC-SGG was efficiently synthesized with a 78% overall yield. SC-SGG inhibited sperm–ZP binding and fertilization of mouse gametes in a concentration-dependent manner, and at 6 µM SC-SGG, the mouse fertilization was zero. SC-SGG inhibited the fertilizing ability of both sperm and eggs, as shown in the pretreatment experiments. Conclusions: SC-SGG was an effective inhibitor of mouse fertilization in vitro. It warrants development to be a non-hormonal contraceptive. Full article

(This article belongs to the Section Pharmacology)

► Show Figures

Figure 1

22 pages, 5127 KiB

Open AccessArticle

Antipyretic Mechanism of Bai Hu Tang on LPS-Induced Fever in Rat: A Network Pharmacology and Metabolomics Analysis

by Ke Pei, Yuchen Wang, Wentao Guo, He Lin, Zhe Lin and Guangfu Lv

Pharmaceuticals 2025, 18(5), 610; https://doi.org/10.3390/ph18050610 - 23 Apr 2025

Abstract

Background: Bai Hu Tang (BHT) is a classic antipyretic in traditional Chinese medicine, however, there is little scientific evidence on the mechanism and material basis of its antipyretic effect. Methods: In LPS-induced febrile rats, after administration of BHT at 42 g/kg [...] Read more.

Background: Bai Hu Tang (BHT) is a classic antipyretic in traditional Chinese medicine, however, there is little scientific evidence on the mechanism and material basis of its antipyretic effect. Methods: In LPS-induced febrile rats, after administration of BHT at 42 g/kg for half an hour, body temperature was measured at hourly intervals for 9 consecutive hours. Then, serum levels of TNF-α, IL-1β, and IL-6, and serum and cerebrospinal fluid (CSF) levels of AVP, cAMP, PGE2, Ca and CRH, and the remaining sera were used for metabolomics. These were then combined with network pharmacology methodology to further analyse the antipyretic effect of BHT and then dock key targets with differential components. Results: Administration of BHT to LPS-induced febrile rats significantly reduced elevated body temperature, TNF-α, IL-1β and IL-6 levels, but serum and CSF levels of AVP, cAMP, PGE2, Ca²⁺ and CRH were significantly elevated compared to the control group. Network pharmacological analyses indicated that the putative functional targets of BHT were regulation of immune responses, associated protein binding and inflammatory responses, and fine-tuning of phosphatase binding and activation of signalling pathways such as MAPK, PI3K, AKT, NF-kB, cAMP and inflammatory pathways. Metabolomic analysis showed that the antipyretic effect of BHT and its mechanism are likely to be involved in fatty acid metabolism, bile acid metabolism and amino acid metabolism in the organism, with L-arginine, glycyrrhetinic acid and N-acetylpentraxine as the main differential metabolites that play a significant role in heat recovery. The results also showed better docking of glycyrrhetinic acid with TNF-α, IL-6R, PTGS2. Conclusions: BHT provides a valuable adjunct to traditional clinical antipyretics by improving body temperature and metabolism and reducing inflammation. Full article

(This article belongs to the Section Pharmacology)

► Show Figures

Figure 1

13 pages, 424 KiB

Open AccessArticle

Impact of Co-Occurring Psychiatric Comorbidities and Substance Use Disorders on Outcomes in Adolescents and Young Adults with Opioid Use Disorder: A Retrospective Cohort Study

by Ligang Liu, Erin R. McKnight, Andrea E. Bonny, Heqing Tao, Pujing Zhao and Milap C. Nahata

Pharmaceuticals 2025, 18(5), 609; https://doi.org/10.3390/ph18050609 - 23 Apr 2025

Abstract

Background/Objectives: Adolescents and young adults (AYAs) with opioid use disorder (OUD) frequently have co-occurring psychiatric conditions and substance use disorders (SUDs). This study evaluated the association of psychiatric comorbidities and other SUDs with treatment retention and urine drug test (UDT) results in AYAs [...] Read more.

Background/Objectives: Adolescents and young adults (AYAs) with opioid use disorder (OUD) frequently have co-occurring psychiatric conditions and substance use disorders (SUDs). This study evaluated the association of psychiatric comorbidities and other SUDs with treatment retention and urine drug test (UDT) results in AYAs with OUD. Methods: This retrospective cohort study included AYAs enrolled in the Substance Use Treatment and Recovery clinic from 2009 to 2022. Participants were categorized into four groups: no comorbidities, only mental health disorders, only other SUDs, and both disorders. Treatment outcomes included retention time and UDT results for medication for OUD (MOUD) and illicit substances, including tetrahydrocannabinol (THC). Kruskal–Wallis tests were used to evaluate differences across groups, and regression models identified variables associated with outcomes. Statistical significance was set at p < 0.05. Results: Among 157 patients, the median retention time was 300 days. Depression (p = 0.04), post-traumatic stress disorder (p = 0.002), and alcohol use disorder (p = 0.04) were associated with prolonged retention, whereas cannabis use disorder predicted shorter retention (p = 0.02). The median proportion of positive UDTs was 0.9 for MOUD, 0.1 for illicit substances, and 0.0 for THC. Older age (p = 0.02) and the use of antidepressants and anxiolytics were associated with greater adherence to MOUD. Cannabis use disorder (p = 0.02) and male sex (p = 0.04) predicted positive UDTs for THC, while MOUD use was linked to lower THC positivity (p = 0.02). The main limitations of this study were related to its retrospective study design and single-center setting. Conclusions: Psychiatric and substance use comorbidities significantly influence retention and treatment adherence in AYAs with OUD. Integrated treatment may improve engagement and outcomes. Further research is needed to tailor interventions for AYAs with co-occurring disorders. Full article

(This article belongs to the Special Issue Drug Safety and Risk Management in Clinical Practice)

► Show Figures

Figure 1

24 pages, 3012 KiB

Open AccessArticle

Structural Activity Relationship Analysis of New Diphenyl PFI-3 Analogues Targeting for the Treatment of Glioblastoma

by Dong-Jin Hwang, Chuanhe Yang, Yinan Wang, Hannah Kelso, Satyanarayana Pochampally, Lawrence M. Pfeffer and Duane D. Miller

Pharmaceuticals 2025, 18(5), 608; https://doi.org/10.3390/ph18050608 - 23 Apr 2025

Abstract

Background/Objectives: Human glioblastoma (GBM) is the most aggressive brain cancer in adults and a highly treatment-refractory malignancy. The overall prognosis for the GBM is extremely poor, with a median survival of 12–14 months after initial diagnosis. Many GBM patients initially respond to [...] Read more.

Background/Objectives: Human glioblastoma (GBM) is the most aggressive brain cancer in adults and a highly treatment-refractory malignancy. The overall prognosis for the GBM is extremely poor, with a median survival of 12–14 months after initial diagnosis. Many GBM patients initially respond to the DNA alkylating agent temozolomide (TMZ), but patients often become therapy-resistant, and tumors recur. We previously reported that treatment with PFI-3, which is a small molecule inhibitor of the bromodomain of the BRG1 subunit of the SW1/SNF chromatin remodeling complex, enhanced the sensitivity of GBM cells to TMZ in vitro and in vivo GBM animal models. Our general objective was to perform an SAR study of new diphenyl PFI-3 analogs. Methods: New structural analogs of PFI-3 were developed, synthesized, and tested for their ability to enhance TMZ-induced GBM cell death by ELISA. Results: Following on the enhanced activity of compounds 2a and 2b, new diphenyl PFI-3 analogs with specific structural adjustments were made to better understand the structural requirements to optimize function. Additionally, several new structurally different candidates (e.g., 4a, 4b, and 5) showed much better efficacy in sensitizing GBM cells to TMZ-induced GBM cell death. Conclusions: Four series of PFI-3 analogs (2, 3, 4, and 5) were designed, synthesized, and tested for the ability to sensitize GBM cells to TMZ-induced cell death. Series 2 optimized the A-ring and R-isomer chirality. Series 3 used a 5-membered linker with weak activity. Series 4’s di-phenyl urea compounds showed better bromodomain inhibition. Series 5’s methoxyphenyl-B-ring analogs were exceptionally strong inhibitors. Full article

(This article belongs to the Section Medicinal Chemistry)

► Show Figures

Figure 1

50 pages, 5274 KiB

Open AccessReview

Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design

by Masaru Tanaka, István Szatmári and László Vécsei

Pharmaceuticals 2025, 18(5), 607; https://doi.org/10.3390/ph18050607 - 22 Apr 2025

Abstract

Background: Quinoline-derived metabolites exhibit notable chemical complexity. What causes minor structural alterations to induce significant changes in disease outcomes? Historically, eclipsed by more straightforward scaffolds, these chemicals serve as a dynamic hub in tryptophan metabolism, linking immunomodulation, excitotoxicity, and cancer. However, many of [...] Read more.

Background: Quinoline-derived metabolites exhibit notable chemical complexity. What causes minor structural alterations to induce significant changes in disease outcomes? Historically, eclipsed by more straightforward scaffolds, these chemicals serve as a dynamic hub in tryptophan metabolism, linking immunomodulation, excitotoxicity, and cancer. However, many of these compounds struggle to cross the blood–brain barrier, and we still do not fully understand how certain structural changes affect their bioavailability or off-target effects. Thus, contemporary research highlights halogenation, esterification, and computational modeling to enhance structure–activity relationships. Summary: This narrative review emphasizes the integration of rational drug design, multi-target ligands, and prodrug methods in enhancing quinoline scaffolds. We explore each molecule’s therapeutic promise, refine each scaffold’s design, and develop each derivative to maximize clinical utility. Translating these laboratory findings into clinical practice, however, remains a formidable challenge. Conclusions: Through the synthesis of findings regarding NMDA receptor antagonism, improved oral bioavailability, and reduced metabolic instability, we demonstrate how single-site changes might modulate excitotoxicity and immunological signaling. Advancing quinoline-based medicines will yield significant advancements in neurology, psychiatry, and oncology. This enlarged framework fosters collaborative discovery, engages various audiences, and advances the field towards next-generation disease-modifying therapies. Robust preclinical validation, patient classification, and comprehensive toxicity evaluations are crucial stages for achieving these extensive endeavors and fostering future therapeutic discoveries globally. Full article

(This article belongs to the Special Issue Kynurenine Pathway: A Novel Therapeutic Opportunity)

► Show Figures

Graphical abstract

2 pages, 130 KiB

Open AccessEditorial

Advancing Neuropharmacology and Neurodegenerative Disease Therapy: Bridging Gaps and Paving New Pathways

by Manuela Leri and Marzia Vasarri

Pharmaceuticals 2025, 18(5), 606; https://doi.org/10.3390/ph18050606 - 22 Apr 2025

Abstract

The Special Issue of Pharmaceuticals, titled “Multi-target drug treatments for neurodegenerative disease”, highlighted recent advancements in neuropharmacology and the therapeutic landscape for neurodegenerative diseases, representing a significant stride forward in our understanding of these complex conditions [...] Full article

(This article belongs to the Special Issue Multi-target Drug Treatments for Neurodegenerative Disease)

19 pages, 13866 KiB

Open AccessArticle

Investigating the Effect and Mechanism of 3-Methyladenine Against Diabetic Encephalopathy by Network Pharmacology, Molecular Docking, and Experimental Validation

by Jiaxin Chu, Jianqiang Song, Zhuolin Fan, Ruijun Zhang, Qiwei Wang, Kexin Yi, Quan Gong and Benju Liu

Pharmaceuticals 2025, 18(5), 605; https://doi.org/10.3390/ph18050605 - 22 Apr 2025

Abstract

Background/Objectives: Diabetic encephalopathy (DE), a severe neurological complication of diabetes mellitus (DM), is characterized by cognitive dysfunction. 3-Methyladenine (3-MA), a methylated adenine derivative, acts as a biomarker for DNA methylation and exhibits hypoglycemic and neuroprotective properties. However, the pharmacological mechanisms underlying 3-MA’s therapeutic [...] Read more.

Background/Objectives: Diabetic encephalopathy (DE), a severe neurological complication of diabetes mellitus (DM), is characterized by cognitive dysfunction. 3-Methyladenine (3-MA), a methylated adenine derivative, acts as a biomarker for DNA methylation and exhibits hypoglycemic and neuroprotective properties. However, the pharmacological mechanisms underlying 3-MA’s therapeutic effects on diabetic microvascular complications remain incompletely understood, owing to the intricate and multifactorial pathogenesis of DE. Methods: This study employed network pharmacology and molecular docking techniques to predict potential targets and signaling pathways of 3-MA against DE, with subsequent validation through animal experiments to elucidate the molecular mechanisms of 3-MA in DE treatment. Results: Network pharmacological analysis identified two key targets of 3-MA in DE modulation: AKT and GSK3β. Molecular docking confirmed a strong binding affinity between 3-MA and AKT/GSK3β. In animal experiments, 3-MA significantly reduced blood glucose levels in diabetic mice, ameliorated learning and memory deficits, and preserved hippocampal neuronal integrity. Furthermore, we found that 3-MA inhibited apoptosis by regulating the expression of Bax and BCL-2. Notably, 3-MA also downregulated the expression of amyloid precursor protein (APP) and Tau while enhancing the expression of phosphorylated AKT and GSK-3β. Conclusions: Our findings may contribute to elucidating the therapeutic mechanisms of 3-MA in diabetic microangiopathy and provide potential therapeutic targets through activation of the AKT/GSK-3β pathway. Full article

(This article belongs to the Section Pharmacology)

► Show Figures

Figure 1

14 pages, 1972 KiB

Open AccessArticle

Larvicidal Potential of Trattinnickia Burserifolia Mart. Essential Oil in Controlling the Malaria Vector in the Amazon

by Gisele Guimarães de Oliveira, Stherfany Mac Donald da Silva, Alessandro Pereira de Souza, Leticia Vieira Anchieta da Silva, Anauara Lima e Silva, Ana Cristina Gonçalves Reis de Melo, Rosemary Aparecida Roque, André Correa de Oliveira, Antonio Alves de Melo Filho and Andreimar Martins Soares

Pharmaceuticals 2025, 18(5), 604; https://doi.org/10.3390/ph18050604 - 22 Apr 2025

Abstract

Background: Among major public health problems, malaria stands out as a tropical disease caused by the Plasmodium protozoan, with mosquitoes of the Anopheles genus serving as its vectors. This disease affects a significant portion of the population, with the highest incidence in the [...] Read more.

Background: Among major public health problems, malaria stands out as a tropical disease caused by the Plasmodium protozoan, with mosquitoes of the Anopheles genus serving as its vectors. This disease affects a significant portion of the population, with the highest incidence in the Legal Amazon, a region responsible for 99% of cases. Although vector control strategies, such as the use of chemical insecticides, are commonly employed, mosquito resistance, environmental impacts, and risks to human health are driving the search for natural alternatives, including the application of essential oils. Objectives: This study investigates the larvicidal activity of Trattinnickia burserifolia Mart. essential oil against Anopheles darlingi. Methods: The essential oil was obtained through hydrodistillation, and its chemical composition was identified using gas chromatography–mass spectrometry. The larvicidal assay followed WHO protocols, testing oil concentrations ranging from 20 to 100 µg mL⁻¹. Results: Efficacy was evaluated after 24, 48, and 72 h to determine LC₅₀, LC₉₀, and other parameters. Chemical composition analysis revealed the presence of 40 compounds, primarily terpenes such as tricyclene, β-pinene, limonene, and α-pinene, which possess bioactive properties that contribute to vector control. The larvicidal activity test showed that LC₅₀ decreased with longer exposure times, indica ting increased efficacy over time. After 72 h, the LC₅₀ was 14.51 µg mL⁻¹, classifying the essential oil as highly effective. Conclusions: Therefore, T. burserifolia Mart. essential oil represents a promising natural alternative for malaria vector control. Full article

(This article belongs to the Special Issue Advances in the Chemical-Biological Knowledge of Essential Oils)

► Show Figures

Graphical abstract

21 pages, 5251 KiB

Open AccessArticle

Silkworm Cocoon—Derived Carbon Dots for Post-Trauma Hemostasis and Tissue Repair

by Xinru Wu, Miaomiao Yao, Xuan Qiao, Lintao Li, Zhiyun Meng, Shuchen Liu, Yunbo Sun, Hui Gan, Xiaoxia Zhu, Zhuona Wu, Ruolan Gu and Guifang Dou

Pharmaceuticals 2025, 18(5), 603; https://doi.org/10.3390/ph18050603 - 22 Apr 2025

Abstract

Background: Traumatic hemorrhage management is challenging due to the need to control severe bleeding and support tissue repair. An ideal material would possess both hemostatic and wound-healing properties. Methods: Silkworm cocoon-derived carbon dots (SC-CDs) were synthesized via a hydrothermal method. After physical and [...] Read more.

Background: Traumatic hemorrhage management is challenging due to the need to control severe bleeding and support tissue repair. An ideal material would possess both hemostatic and wound-healing properties. Methods: Silkworm cocoon-derived carbon dots (SC-CDs) were synthesized via a hydrothermal method. After physical and chemical characterization using techniques such as HR-TEM and XPS, their hemostatic efficacy was assessed in rat liver injury, tail transection, and mouse coagulation disorder models. Moreover, the effects of the SC-CDs on platelet aggregation and activation were evaluated. The potential of the SC-CDs to promote wound healing was investigated through cell scratch assays and a mouse full-thickness skin defect model. Results: The SC-CDs showed a high quantum yield (12.9% ± 0.42%), with low hemolytic activity and cytotoxicity. In the hemostasis models, the SC-CDs significantly reduced the bleeding time and volume. In the rat liver injury model, the bleeding time was shortened from 152.67 ± 4.16 s (Control) to 55.33 ± 9.50 s (p < 0.05). In the rat tail transection model, the bleeding volume was reduced from 1.71 ± 0.16 g (Control) to 0.4 ± 0.11 g (p < 0.05). In the mouse coagulation disorder model, an 8 mg/kg dose reduced the bleeding volume to 11.80% ± 0.39% of that of the Control (p < 0.05). Mechanistic studies suggested enhanced platelet activation and aggregation. In the wound healing experiments, the SC-CDs reduced the wound area (88.53 ± 11.78 mm² (Control) vs. 70.07 ± 6.71 mm² (SC-CDs), p < 0.05) and promoted fibroblast migration (24 h scratch width: 372.34 ± 9.06 μm (Control) vs. 259.49 ± 36.75 μm (SC-CDs), p < 0.05). Conclusions: SC-CDs show promise for hemorrhage management and tissue regeneration, with potential applications in cases of internal bleeding or coagulation disorders. Full article

(This article belongs to the Section Pharmaceutical Technology)

► Show Figures

Graphical abstract

24 pages, 3945 KiB

Open AccessArticle

Medicinal Phytocompounds as Potential Inhibitors of p300-HIF1α Interaction: A Structure-Based Screening and Molecular Dynamics Simulation Study

by Muhammad Suleman, Abrar Mohammad Sayaf, Sohail Aftab, Mohammed Alissa, Abdullah Alghamdi, Suad A. Alghamdi, Mohammed A. Alshehri, Kar Kheng Yeoh, Sergio Crovella and Abdullah A. Shaito

Pharmaceuticals 2025, 18(4), 602; https://doi.org/10.3390/ph18040602 - 21 Apr 2025

Abstract

Background: Hypoxia plays a key role in cancer progression, mainly by stabilizing and activating hypoxia-inducible factor-1 (HIF-1). For HIF-1 to function under low oxygen conditions, it must interact with the transcriptional coactivator p300, a critical step for promoting cancer cell survival and adaptation [...] Read more.

Background: Hypoxia plays a key role in cancer progression, mainly by stabilizing and activating hypoxia-inducible factor-1 (HIF-1). For HIF-1 to function under low oxygen conditions, it must interact with the transcriptional coactivator p300, a critical step for promoting cancer cell survival and adaptation in hypoxic environments. Methods: Consequently, we used drug design and molecular simulation techniques to screen phytochemical databases, including traditional Chinese and African medicine sources, for compounds that could disrupt the p300/HIF-1 interaction. Results: In this study, we identified potential compounds with high docking scores such as EA-176920 (−8.719), EA-46881231 (−8.642), SA-31161 (−9.580), SA-5280863 (−8.179), NE-5280362 (−10.287), NE-72276 (−9.017), NA-11210533 (−10.366), NA-11336960 (−7.818), TCM-5281792 (−12.648), and TCM-6441280 (−9.470 kcal/mol) as lead compounds. Furthermore, the compound with the highest docking score from each database (EA-176920, SA-31161, NE-5280362, NA-11210533, and TCM-5281792) was subjected to further analysis. The stable binding affinity of these compounds with p300 was confirmed by Post-simulation binding free energy (−22.0020 kcal/mol, −25.4499 kcal/mol, −32.4530 kcal/mol, −33.9918 kcal/mol, and −57.7755 kcal/mol, respectively) and KD analysis. Moreover, the selected compounds followed the Lipinski rules with favorable ADMET properties like efficient intestinal absorption, high water solubility, and no toxicity. Conclusions: Our findings highlight the potential of natural compounds to target key protein–protein interactions in cancer and lay the groundwork for future in vitro and in vivo studies to explore their therapeutic potential. Specifically, disrupting the p300/HIF-1 interaction could interfere with hypoxia-driven pathways that promote tumor growth, angiogenesis, and metastasis, offering a promising strategy to suppress cancer progression at the molecular level. Full article

(This article belongs to the Special Issue Exploring the Anticancer and Immunomodulatory Mechanisms of Phytochemicals and Natural Bioactive Compounds)

► Show Figures

Figure 1

32 pages, 1564 KiB

Open AccessSystematic Review

Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis

by Nathália Mendes Machado, Maria Vitória Barroso Oliveira, Karina Quesada, Jesselina Francisco dos Santos Haber, Ricardo José Tofano, Claudio José Rubira, Tereza Lais Menegucci Zutin, Rosa Direito, Eliana de Souza Bastos Mazuqueli Pereira, Camila Marcondes de Oliveira, Ricardo de Alvares Goulart, Vitor Engrácia Valenti, Kátia Portero Sloan, Lance Alan Sloan, Lucas Fornari Laurindo and Sandra Maria Barbalho

Pharmaceuticals 2025, 18(4), 601; https://doi.org/10.3390/ph18040601 - 20 Apr 2025

Abstract

Background: Lipid-lowering therapies are an option for stabilizing lipid levels. Icosapent ethyl (IPE) is a highly purified formulation of eicosapentaenoic acid, which can reduce lipid action, improve plaque stabilization, reduce platelet aggregation, lower TG, and prevent cardiovascular events. IPE is frequently used with [...] Read more.

Background: Lipid-lowering therapies are an option for stabilizing lipid levels. Icosapent ethyl (IPE) is a highly purified formulation of eicosapentaenoic acid, which can reduce lipid action, improve plaque stabilization, reduce platelet aggregation, lower TG, and prevent cardiovascular events. IPE is frequently used with statins to manage elevated TG levels. However, the evidence on IPE as a lipid-lowering agent is limited, and no updated systematic review and meta-analysis have been published considering the recent advancements in the field and newly published studies. Therefore, we aim to fill this gap. Methods: We used the PRISMA guidelines and the PICO (Population, Intervention, Comparison, and Outcome) framework to conduct this review, aiming to answer the question, “Can IPE benefit patients at cardiovascular risk?” GRADE was used to evaluate evidence levels to adhere to the highest criteria. Results: Predominantly, the evaluated population presented TG levels between ≥135 mg/dL and 500 mg/dL and LDL-C levels between >40 mg/dL and ≤100 mg/dL. The included studies showed a reduction in TG and LDL-C and a decrease in cardiovascular events. It means that, according to our systematic review evidence analysis, IPE has been effective in lowering blood lipid levels, including TG, and reducing cardiovascular death and events, such as non-fatal stroke or hospitalization for unstable angina. However, it is worth noting that these results were primarily from patients undergoing statin therapy. According to our meta-analysis, IPE may not be considered a lipid-lowering drug, as limited action associated with its use was evident in the quantitative results. However, caution is necessary, as only two studies were suitable for inclusion due to the differing outcomes in the analyzed samples. Conclusions: Despite the quantitative synthesis, IPE possesses anti-inflammatory, anti-thrombotic, and anti-atherogenic properties, highly related to cardiovascular protection. Based on our included studies, IPE was considered a promising therapy for atherosclerotic cardiovascular disease in conjunction with other lipid-lowering therapies, particularly statins, for patients with extremely high TG levels. The limitations of the reviewed studies may include small sample sizes, varying outcomes, and a small duration of interventions. Future clinical trials with similar outcomes, sample sizes, and intervention durations must be designed, and updated meta-analyses must be published in the following years to fully assess the effects of IPE as a lipid-lowering and cardiovascular protector drug. Full article

(This article belongs to the Special Issue Pharmacotherapy of Dyslipidemias, 2nd Edition)

► Show Figures

Figure 1

Journal Description

Pharmaceuticals

Latest Articles

Journal Menu

Journal Browser

Highly Accessed Articles

Latest Books

E-Mail Alert

News

Topics

Conferences

Special Issues

Topical Collections

Conference Reports

Further Information

Guidelines

MDPI Initiatives

Follow MDPI